Medical News

RSS

Solos Endoscopy to launch new urology product line

Solos Endoscopy, Inc. is pleased to announce that the Company is set to introduce a new product line consisting of urology surgical and diagnostic instruments.

24 Feb 2011

Oncolytics completes patient enrollment in REOLYSIN trial to treat metastatic colorectal cancer

Oncolytics Biotech Inc. announced today that enrollment has been completed in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases.

23 Feb 2011

Pharmagesic to acquire WEX shares

Pharmagesic Inc. announced today that the offer by its wholly-owned subsidiary, 7735308 Canada Limited to acquire all of the outstanding restricted voting shares of WEX Pharmaceuticals Inc. not already owned by Pharmagesic for C$0.14 cash per WEX Share has been extended to 5:00 p.m. on March 10, 2011.

23 Feb 2011

ACT receives patent for its single-blastomere technology

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent on its "single-blastomere" technique. Patent Number 7,893,315 broadly covers ACT's proprietary single-blastomere technology that provides a non-destructive alternative for deriving human embryonic stem cell lines.

23 Feb 2011

California researchers receive InHealth grant to evaluate device-intensive procedures

The Institute for Health Technology Studies has awarded a $263,000 grant to a research team at the University of California, Berkeley, to identify and analyze the strategies that hospital systems employ to evaluate and purchase implantable medical devices for cardiac, spinal, and orthopedic procedures.

23 Feb 2011

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Novo Nordisk announced today that a Biologic License Application has been submitted to the U.S. Food and Drug Administration requesting the approval of a recombinant factor XIII compound for the vast majority of patients with congenital factor XIII deficiency, an inherited bleeding disorder.

From Novo Nordisk 23 Feb 2011

PCI Biotech completes patient inclusion in PC-A11 phase I/II study to treat cancer

PCI Biotech the Norwegian biopharmaceutical company, reported today that it has completed the inclusion of patients in its phase I/II study of its lead candidate PC-A11 in cancer patients.

23 Feb 2011

New research: Alzheimer's disease may be easily misdiagnosed in elder people

New research shows that Alzheimer's disease and other dementing illnesses may be easily misdiagnosed in the elderly, according to early results of a study of people in Hawaii who had their brains autopsied after death. The research is being released today and will be presented as part of a plenary session at the American Academy of Neurology's 63rd Annual Meeting in Honolulu April 9 to April 16, 2011.

23 Feb 2011

Researchers identify low-dose, two-drug cocktail that reduces noise-induced hearing loss in mice

Whether on a battlefield, in a factory or at a rock concert, noise-induced hearing loss is one of the most common hazards people face. Researchers at Washington University School of Medicine in St. Louis have identified a low-dose, two-drug cocktail that reduces hearing loss in mice when given before they are exposed to loud noise. The drugs, already FDA-approved for other conditions, also treat hearing loss after noise exposure.

23 Feb 2011

FDA clears Agendia's breast cancer recurrence assay

Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration clearance for MammaPrint, its widely used breast cancer recurrence assay.

23 Feb 2011

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

Sunesis Pharmaceuticals, Inc. today announced that vosaroxin, the Company's lead drug candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration for the potential treatment of relapsed or refractory acute myeloid leukemia in combination with cytarabine.

23 Feb 2011

Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure

Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.

23 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

FDA clears Entellus Medical's new FinESS Endoscope

Entellus Medical, a Minnesota-based medical technology company, announced today that the U.S. Food and Drug Administration cleared the company's new FinESS Endoscope.

23 Feb 2011

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Aestus Therapeutics, Inc., announced today that it has initiated screening of patients for a clinical trial to evaluate the efficacy of its novel pain therapeutic, ATx08-001. This placebo-controlled, two-dose level study will test the efficacy of ATx08-001 in reducing the pain following an outbreak of shingles.

23 Feb 2011

GTCR to acquire Sterigenics International

GTCR, a leading private equity firm, today announced it has signed a definitive agreement with Silverfleet Capital and PPM America Capital Partners to acquire Sterigenics International, the leading global provider of contract sterilization and ionization services for medical devices, food products, and advanced applications.

23 Feb 2011

Australia’s top scientist takes on top job

Today, the man who is known for one of Australia’s greatest medical achievements – the development of a cervical cancer vaccine – has been appointed as Chief Executive Officer of the Translational Research Institute (TRI) in Brisbane, Queensland.

23 Feb 2011

Cell phones may lead to stimulation of parts of brain - Speculation on cancer continues

There is still debate as to whether cell phones damage the brain. The cell phone industry, along with nearly all major national and international medical associations have always responded with the same answer that there is no evidence that cell phone radiation can even affect the brain, let alone cause cancer.

23 Feb 2011

Biological pathways in PTSD revealed: Study

Up to 20% of the population exposed to a horror of a war, trauma or abuse may go on to develop post-traumatic stress disorder. PTSD, as it is better known, is a debilitating psychiatric disorder marked by flashbacks and nightmares. Till date the biological basis for PTSD was unclear. But a new study offers clues about why some people rebound from horrific events while others relive them, and may lead to predictive tests and even treatments.

23 Feb 2011

Mass polio vaccination campaigns in Burma and Sudan

After a seven-month-old baby was diagnosed with polio, Myanmar is planning a mass polio vaccination said the United Nations Children’s Fund. UNICEF revealed that just one case is enough to trigger an “emergency response”, and health officials promptly vaccinated 10,000 children in the Mandalay region, central Myanmar, after the illness was first suspected in December 2010.

23 Feb 2011

Medical News

Solos Endoscopy to launch new urology product line

Oncolytics completes patient enrollment in REOLYSIN trial to treat metastatic colorectal cancer

Pharmagesic to acquire WEX shares

ACT receives patent for its single-blastomere technology

California researchers receive InHealth grant to evaluate device-intensive procedures

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

PCI Biotech completes patient inclusion in PC-A11 phase I/II study to treat cancer

New research: Alzheimer's disease may be easily misdiagnosed in elder people

Researchers identify low-dose, two-drug cocktail that reduces noise-induced hearing loss in mice

FDA clears Agendia's breast cancer recurrence assay

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

FDA clears Entellus Medical's new FinESS Endoscope

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

GTCR to acquire Sterigenics International

Australia’s top scientist takes on top job

Cell phones may lead to stimulation of parts of brain - Speculation on cancer continues

Biological pathways in PTSD revealed: Study

Mass polio vaccination campaigns in Burma and Sudan

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News